On June 9, an advisory committee to the Food and Drug Administration (FDA) endorsed the clinical benefit of and granted Priority Review to lecanemab (Brand Name: Leqembi), an anti-amyloid treatment de…
October 14, 2026
On June 9, an advisory committee to the Food and Drug Administration (FDA) endorsed the clinical benefit of and granted Priority Review to lecanemab (Brand Name: Leqembi), an anti-amyloid treatment de…